

## TARGET MARKET DETERMINATION - OPTIONS

**MADE BY:** Dimerix Limited (ACN 001 285 230) of 425 Smith Street, Fitzroy, Victoria, 3065  
(the Company)

**PRODUCTS:** This Target Market Determination (**TMD**) relates to the following products:

- unlisted options each to acquire one fully paid ordinary share in the capital of the Company (each a **Share**) with an exercise price of \$0.126 (12.6 cents) and expiry date of 31 March 2024 (**Short Term New Options**); and
- listed DXBO options each to acquire one Share with an exercise price of \$0.154 (15.4 cents) and expiry date of 30 June 2025 (**Long Term New Options**).

The products are proposed to be offered and issued as follows, each of which has been approved for issue by the shareholders of the Company:

- 11,363,636 Long Term New Options to Mercer Street Global Opportunity Fund, LLC, a US-based investment fund managed by Mercer Street Capital Partners, LLC (together, **Mercer**) in accordance with the terms of the Convertible Securities Agreement between the Company and Mercer, under the **Noteholder Offer**.
- 117,590 Short Term New Options and 117,590 Long Term New Options to Dr James Williams (or his nominee), issued as free-attaching to shares (such shares to be issued at \$0.08 (8 cents) per share), under the **Related Party Shortfall Offer**.
- An aggregate of 1,297,416 Long Term New Options to related parties (or their respective nominee) who were sub-underwriters, or irrevocably committed to take up, a portion of the shortfall of the Entitlement Offer (**Sub-Underwriter Option Offer**), on the basis of the number of Long Term New Options to be issued under the Sub-Underwriter Option Offer being equal to two and a half (2.5) Long Term New Options for every \$1 sub-underwritten or irrevocably committed under the Entitlement Offer.
- 4,500,000 Long Term New Options to Bell Potter Securities Limited, as part consideration for partial underwriting of the Entitlement Offer, under the Underwriter Option Offer.

Each of the above offers and issues are described in and made under the Company's prospectus of the Company dated 26 June 2023 (**Prospectus**). Capitalised terms in this TMD not defined herein are as defined in the Prospectus.

**EFFECTIVE DATE:** 26 June 2023

This target market determination (**TMD**) has been prepared by the Company in relation to the offers of options which are made by the Company under the Prospectus. The Prospectus was lodged with Australian Securities and Investments Commission (**ASIC**) on 26 June 2023 and was released to ASX on

that date. An electronic version of the Prospectus is available in the ASX announcements of the Company ([www2.asx.com.au/markets/trade-our-cash-market/announcements.dxb](http://www2.asx.com.au/markets/trade-our-cash-market/announcements.dxb)).

The offers of securities described above are collectively referred to in this TMD as the **Offers** and the options offered under the Offers are collectively referred to in this TMD as the **Options**.

The Company will send a copy of the Prospectus, or instructions about how to download it, to those parties named in the Prospectus to whom an invitation to apply for Options it be provided. A copy can also be downloaded from the ASX at the website above. Readers of this TMD should also obtain and carefully read and consider the Prospectus in full and consult their professional adviser if they have any questions regarding the contents of the Prospectus or this TMD. Readers of this TMD who are eligible and wish to acquire Options under the applicable Offer (being those persons named in the Prospectus or, as applicable, their nominee) will need to obtain and read a copy of the Prospectus and complete an application in the form or manner that will be in, accompanied by or described in, the Prospectus. This TMD is not a disclosure document for the purposes of the Corporations Act and therefore has not been lodged, and does not require lodgement, with ASIC.

This TMD is not to be treated as a full summary of the product terms and conditions and is not intended to provide financial advice. Investors should refer to the Prospectus for the terms and conditions of the product and when making a decision in respect of the product.

#### Target market

The Offers are only made to and are therefore only capable of acceptance by the parties named in the Prospectus as being capable of accepting the respective Offers (or, where applicable, their nominee).. Where applicable, the specific parties named in the Prospectus as being capable of accepting the respective Offer may tell the Company in writing they wish Options to be issued to their nominee. The specific parties are responsible for confirming their nominees are suitable recipients of the Options.

The information below summarises the overall class of investors that fall within the target market for the Options, based on the key attributes of the product and the objectives, financial situation and needs that they have been designed to meet. The Options have been designed for investors whose likely objectives, financial situation and needs are aligned with the product.

The Company expects an investment by acquiring the Options will be suitable to investors who take a short to medium term outlook on their investment and are accustomed to making speculative investments in the life sciences sector particularly in companies involved in drug discovery and development including clinical trials.

Investors with a short to medium term outlook for their investment will benefit from the ability to trade the underlying Shares issued on exercise of the Options prior to the respective expiry dates should the exercise price be lower than the Share price.

Investors with a short-term outlook for their investment may also benefit from the Long Term New Options potentially being listed on ASX. Investors with a medium term outlook will benefit from the ability to exercise the Options prior to the respective expiry dates and receive Shares and exposure to potential upside on the Shares of the Company into the future.

An exercise price is required to be paid to acquire Shares on exercise of Options. As such, the capacity to realise the underlying value of the Options could require that they be exercised on or before the

expiry date. Investors in the target market will need be in a financial position to have sufficient available funds so as to facilitate an exercise of the Options prior to the expiry date. Investors' ability to sell the Long Term New Options prior to the expiry date or to sell Shares issued upon exercise of Options may be limited by a lack of liquidity in the trading of the Long Term New Options and/or Shares, and the price of the Long Term New Options and/or the Shares.

It is also expected that the target market of investors will be able to withstand potential fluctuations in the value of their investment. Options and Shares issued upon exercise of the Options offer no income guarantee or capital protection for investors.

The Company considers that an investment in the Options and Shares issued upon exercise of the Options is highly speculative, such that an investment in the Company may not be appropriate for an investor who would not be able to bear the loss of some or all of their investment. Investors should also have sufficient financial literacy and resources (including appropriate advisers) to understand and appreciate the potential risk of investing in the Company (including the Options and Shares issued upon exercise of the options) as an asset class generally and the more specific risks of investing in the Company as an ASX listed life sciences entity including risks as described in the Prospectus.

#### Distribution conditions

The offers of Options are only being made under the Prospectus. Acceptances of or applications for Options can only be made under the Prospectus by completing an application in the form or manner that will be in, accompanied by or described in, the Prospectus.

The Company will include a copy of this TMD on its website, [www.dimerix.com](http://www.dimerix.com). By making an application for Options under the Prospectus, the applicant warrants that they have obtained, read and understood this TMD (as the TMD applicable to the Options) and that they meet the eligibility criteria of, and fall within, the target markets set out in this TMD.

#### Review triggers

The Options are being offered under the Prospectus for limited offer periods as set out or provided for in the Prospectus. The Options will no longer be available for investment by way of issue under the Prospectus following close of the applicable offer period(s). Accordingly, this TMD applies between the lodgement of the Prospectus and the issue of the Options under the Prospectus (**Offer Period**) unless the Offers are withdrawn or the issue of the Options otherwise does not proceed.

To allow the Company to determine whether circumstances exist indicating this TMD is no longer appropriate to the Options, the following review triggers apply for the Offer Period:

- the Company lodges a supplementary prospectus relevant to the Offers or the issue of the Options or a replacement prospectus with ASIC;
- a new offer of Options that requires preparation of a further disclosure document is made;
- any event or circumstance occurs that materially changes a factor that was taken into account in making this TMD;

- the existence of a significant dealing of the Options that is not consistent with this TMD (noting on-sale of Long Term New Options on-market (if listed), exercise of the Options and on-sale of Shares issued upon exercise of the Options is not considered to be a significant dealing);
- ASIC raises concerns with the Company regarding the adequacy of the Prospectus, the design or distribution of the Options, or this TMD; and
- there are material changes to the regulatory environment that applies to an investment in the Options.

#### Review period

If a review trigger occurs during the Offer Period, the Company will review this TMD in light of the review trigger. The Company will otherwise complete a review of the TMD immediately prior to the issue of the Options under the Offers.

#### Information reporting

The requirements of all distributors to report to the Company are set out below:

##### *Whether the distributor received complaints about the Options*

- During the Offer Period, distributors are to give the Company a written report within 10 business days after the end of each quarter. A written report also to be given the Company 10 business days after the end of the Offer Period.
- Each report is to include the number of complaints received and a summary of the nature of each complaint or a copy of each complaint.

##### *A significant dealing of the Options that is not consistent with this TMD*

- Give the Company a report as soon as reasonably practicable (and in any event no more than 10 business days) after the significant dealing occurs.
- Each report is to include details of the significant dealing and reasons the distributor considers the significant dealing is not consistent with this TMD.

##### *Summary of steps to be taken by the distributor to ensure its conduct was consistent with this TMD*

Within 10 business days after close of the Offers distributors are to give the Company a report which includes a summary of steps taken by the distributor to ensure its conduct was consistent with this TMD.

#### Other offers under the Prospectus

The Prospectus contains other offers including an offer of convertible notes to a single proposed recipient. This TMD is made solely in respect of the Options and the Offers of options. The Company has issued, and relevant readers should refer to, a separate TMD in respect of the convertible notes offered under the Prospectus. That TMD is available at the Company's website at [www.dimerix.com](http://www.dimerix.com).

Contact

For further information please contact the Company at: [investor@dimerix.com](mailto:investor@dimerix.com)